Late recurrence of a tumor of Ewing’s sarcoma family of tumors: report of a case

Takamasa Yun1*, Hidemi Suzuki1, Teruaki Mizobuchi1, Yuichi Sakairi1, Kaoru Nagato1, Takahiro Nakajima1, Takekazu Iwata1, Shigetoshi Yoshida1, Yukio Nakatani2 and Ichiro Yoshino1

Abstract

A 27-year-old female presented with a history of a right chest wall tumor at 3 years of age. At that time, the tumor was surgically resected and diagnosed as Ewing’s sarcoma (EWS), and postoperative chemoradiotherapy was administered. The patient remained disease-free for 25 years. At age 27, chest computed tomography revealed a mass adjacent to the anterolateral thoracic wall. After surgery, the diagnosis was primitive neuroectodermal tumor (PNET). She died of the disease 10 months later. PNET and EWS were integrated into a single item in the 2002 WHO classification; thus, they are considered clinically and pathologically identical. The morphologic, immunohistochemical, and molecular biological characteristics of both specimens showed that the second tumor was a local recurrence of Ewing’s sarcoma family of tumors (ESFT). Our case is the longest duration local recurrence reported. Long-term recurrences of ESFT and patients with recurrent ESFT have a poor prognosis; thus, long-term follow-up is necessary.

Keywords: Ewing’s sarcoma family of tumors; Primitive neuroectodermal tumor; Late recurrence

Background

Tumors of Ewing’s sarcoma family of tumors (ESFT) are malignant tumors that originate in the central and peripheral nervous systems and soft tissues in children and adolescents. The prognosis is generally poor. However, recent treatment outcomes of ESFT have improved with the use of multimodal therapy [1]. Advances in molecular biology have revealed common chromosomal translocations such as EWS-FLI-1 among Ewing’s sarcoma (Ewing’s sarcoma of the bone and extraosseous Ewing’s sarcoma) and related diseases, such as primitive neuroectodermal tumor (PNET) and Askin’s tumor [2].

PNET and Ewing’s sarcoma (EWS) were integrated into a single item in the 2002 WHO classification; thus, they are considered clinically and pathologically identical. Late relapses are seldom described. We report a patient with an ESFT who had a recurrence 25 years after initial surgery and postoperative chemoradiation.

Case presentation

A patient presented to us with a remote history of treatment for a right chest wall tumor. At 3 years of age, she was noted to have a very large chest wall tumor in the anterior thoracic cavity (Figure 1a) without distant metastases; she subsequently underwent surgical resection. The specimen revealed malignant small round cells with rosette formation and was positive for CD99 (MIC2 gene product) by immunohistochemical staining, consistent with a diagnosis of EWS (Figure 1b,c,d). The patient was administered three cycles of postoperative chemotherapy that consisted of vincristine, cyclophosphamide, Adriamycin, and actinomycin-D, as well as local irradiation with a total dose of 40 Gy. Her postoperative course was uneventful, and she remained disease-free for 25 years.

At 27 years of age, she was referred to our institution with the chief complaint of chest pain. Her chest X-ray demonstrated a well-defined, round mass in the right thoracic cavity (Figure 1a) without distant metastases; she subsequently underwent surgical resection. The specimen revealed malignant small round cells with rosette formation and was positive for CD99 (MIC2 gene product) by immunohistochemical staining, consistent with a diagnosis of EWS (Figure 1b,c,d). The patient was administered three cycles of postoperative chemotherapy that consisted of vincristine, cyclophosphamide, Adriamycin, and actinomycin-D, as well as local irradiation with a total dose of 40 Gy. Her postoperative course was uneventful, and she remained disease-free for 25 years.

At 27 years of age, she was referred to our institution with the chief complaint of chest pain. Her chest X-ray demonstrated a well-defined, round mass in the right upper lung field. A computed tomography (CT) scan of the chest revealed a distinct mass adjacent to the anterolateral thoracic wall (Figure 2a), and metastatic workup was negative. Physical examination was unremarkable. Hematology and blood chemistry values were within the normal ranges, and tumor markers (carcinoembryonic antigen, neuron-specific enolase, squamous cell carcinoma-
related antigen, and α-fetoprotein) were lower than the standard values.

As either radiation-induced sarcoma or a local recurrence of EWS was suspected, we performed extirpation of the tumor and chest wall (the left second to the fourth ribs), partial resection of the right lung, and reconstruction of the chest wall (Figure 2b). Intraoperative blood loss was 800 g, and the operation took 4 h and 51 min.

Pathologic findings were identical to those of the original chest wall tumor, with small round cells and extensive necrosis (Figure 2c). The specimen stained positively
with antibodies to CD99 (Figure 2d). Immunohistochemical and histochemical staining showed that the tumor was positive for chromogranin, synaptophysin, and neuron-specific enolase and negative for thyroid transcription factor-1, myogenin, and desmin. Fluorescence in situ hybridization analysis using a EWSR1 break-apart probe identified the rearranged EWSR1 gene in both cases. Thus, histopathologically, the tumor was diagnosed as a PNET. Four cycles of VDC (vincristine, doxorubicin, cyclophosphamide) chemotherapy and two cycles of IE (ifosfamide, etoposide) and high-dose L-PAM (melphalan) and radiotherapy of left thigh bone for a total dose of 30 Gy was administered after the second operation. She had recurrences in the right chest wall and upper middle lobe and metastases in the skull, rib, vertebrae, ilium, and thigh bone. She died of carcinomatous lymphangiosis 10 months after the second surgery.

Discussion

In 1921, James Ewing reported a rare type of sarcoma in children, adolescents, and young adults that is a highly malignant tumor of the bone and soft tissue, composed of small round cells [3]. Separately, Stout et al. reported in 1918 that a PNET is an ulnar nerve-derived small round cell tumor with rosette formation that develops in soft tissues in young individuals [4]. The first small round cell tumor of chest wall origin was reported in a pediatric patient by Askin, and these tumors are referred to as Askin tumors [5]. An Askin tumor is a PNET that develops from the soft tissues of the chest wall in childhood. At that time, our case might have been termed an Askin tumor.

Pathologically, EWS/PNET is composed of small, round, uniform cells with characteristic small-sized rosette formation. These tumors, both with a poor prognosis, were described as separate entities in the small round cell tumor group in the second version of the WHO classification published in 1993. However, with recent improvements in molecular biology, a translocation (11; 22) (q24; q12) specific to both EWS and PNET has been identified, and the EWS-FLI-1 fused gene was identified at the cleavage site of this translocation. They therefore were subsequently integrated into a single item (Ewing’s sarcoma/PNET) in the WHO classification, published in 2007 [6]. The ESFT includes EWS of the bone, extrasosseous EWS, and PNET of the bone or soft tissue.

The most useful immunohistochemical reagent for the diagnosis of ESFT is the monoclonal antibody CD99, which recognizes a cell surface protein. Specimens stain strongly positive with the CD99 antibody in more than 90% to 95% of cases of reported ESFT.

Chest wall ESFT tumors are rare, have a high rate of local recurrence, and frequently are metastatic at presentation. In a report of 84 thoracic PNET cases by Biswas et al., patient age ranged from 3 to 40 years (mean age = 15 years) and tumor diameter ranged from 1.6 to 20.0 cm (mean diameter = 9.0 cm). It occurred most commonly in the ribs (54%), the scapula (25%), and the chest wall (14%), with a male predominance (70%). Twenty-seven (32%) patients had metastatic disease at diagnosis. An independent prognostic factor for PNET is the presence of metastatic disease [7]. The median relapse-free interval (RFI) after treatment was 17 months (range, 5 to 90 months). In contrast to the dramatic improvement in survival for ESFT, the prognosis after recurrent disease remains poor, especially for patients with a RFI of less than 24 months [8].

The morphologic, immunohistochemical, and molecular biological characteristics from both specimens supported that the second tumor was a local recurrence of an ESFT. Several prior studies established that the longest time until recurrence of ESFT was 19 years [9]. Our case demonstrates the possibility of very late local recurrence of ESFT.

We report a case of locally recurrent ESFT 25 years after initial treatment. To our knowledge, no case with such late local relapse as our case has been reported to date.

Conclusions

We report a rare case of chest wall ESFT in a 27-year-old female. A right thoracic recurrence was surgically resected 25 years after the primary tumor, but the patient died of the disease 10 months after surgery. Our case suggests that patients with ESFT should undergo lifetime surveillance. Generally, it is difficult to detect recurrence from clinical symptom of the patients. Patients should be under observation using periodical CT, bone scintigraphy, or PET periodically.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

All authors participated in the operation or management of the patient in this case report and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Dr. Masanori Hisaoka (Department of Pathology and Oncology, University of Occupational and Environmental Health, Japan) for the assistance with the pathological diagnosis and for performing the molecular biological analysis of the EWS gene.

Author details

1Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba 260-8670, Japan. 2Department of Pathology, Chiba University Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba 260-8670, Japan.
Received: 28 September 2014 Accepted: 9 April 2015
Published online: 24 April 2015

References
1. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone (in English). N Engl J Med. 2003;348:694–701.
2. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors—a subgroup of small-round-cell tumors defined by specific chimeric transcripts (in English). N Engl J Med. 1994;331:294–9.
3. Ewing J. The classic: diffuse endothelioma of bone. Proceedings of the New York Pathological Society. 1921;12:17 (in English). Clin Orthop Relat Res. 2006;450:25–7.
4. Stout AP. A tumor of the ulnar nerve. Proc NY Pathol Soc. 1918;18:2–12.
5. Askin FB, Rosai J, Sibley RK, Dehner LP, McAlister WH. Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis (in English). Cancer. 1979;43:2438–51.
6. Fletcher CD, Umrni K, Merten F. World Health Organization classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2007. p. 297–300.
7. Biswas B, Agarwala S, Shukla NK, Deo S, Sharma D, Thulkar S, et al. Evaluation of outcome and prognostic factors in thoracic primitive neuroectodermal tumor: a study of 84 cases. Ann Thorac Surg. 2013;96:2006–14.
8. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol. 2005;23:4354–62.
9. Hanna SA, David LA, Gikas PD, Tindall AJ, Cannon SR, Briggs TW. Very late local recurrence of Ewing's sarcoma—can you ever say 'cured'? A report of two cases and literature review (in English). Ann R Coll Surg Engl. 2008;90:W12–5.

Submit your manuscript to a SpringerOpen journal and benefit from:
► Convenient online submission
► Rigorous peer review
► Immediate publication on acceptance
► Open access: articles freely available online
► High visibility within the field
► Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com